Many MIT CCR members are using vertebrate model organisms to study the role of known or putative cancer genes in both normal development and tumorigenicity. This includes a variety of mutant mouse strains that carry gain-of-function, loss-offunction and/or conditional alleles as well as a large collection of zebrafish strains that carry inactivating viral insertions within numerous genes essential for embryonic development. To support these studies, it is essential that researchers can correctly diagnose the resulting phenotypes and also recover tissue samples to investigate the underlying molecular changes. The Histology Core Facility?s mission is to provide CCR researchers with state-of-the-art histological services. The facility carries out the processing and sectioning of tissue samples and the generation of slides on a fee-for-service basis. It also provides cutting-edge intellectual and technical expertise. This includes advice on the generation and fixation of tissue samples and the availability and use of various staining procedures. In addition, a veterinary pathologist, Dr. Roderick Bronson, works in the Facility one day a week. Dr. Bronson is an internationally recognized expert in mouse pathology, and he is available to meet with CCR researchers to assist in the analysis of slides and the diagnosis of developmental and tumor phenotypes. This provides expert training of CCR students, postdocs and staff in histology and has played a significant role in promoting collaborative interactions, both between CCR investigator laboratories and with the wider cancer community, through the identification of shared or related phenotypes in different model systems. The centralization of histological analysis allows the MIT CCR to provide its investigators with a comprehensive range of services while minimizing staff and equipment costs and space requirements. Price comparisons show that the cost to CCR Investigators is highly competitive with those of other academic histology facilities within the Boston/Cambridge area and significantly cheaper than commercial options.
| Huang, Hsin-Ho; Qian, Yili; Del Vecchio, Domitilla (2018) A quasi-integral controller for adaptation of genetic modules to variable ribosome demand. Nat Commun 9:5415 |
| Guimarães, Pedro P G; Gaglione, Stephanie; Sewastianik, Tomasz et al. (2018) Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. ACS Nano 12:912-931 |
| Nath, Samir R; Yu, Zhigang; Gipson, Theresa A et al. (2018) Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction. J Clin Invest 128:3630-3641 |
| Moynihan, Kelly D; Holden, Rebecca L; Mehta, Naveen K et al. (2018) Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability. Cancer Immunol Res 6:1025-1038 |
| Rothenberg, Daniel A; Taliaferro, J Matthew; Huber, Sabrina M et al. (2018) A Proteomics Approach to Profiling the Temporal Translational Response to Stress and Growth. iScience 9:367-381 |
| Kimmerling, Robert J; Prakadan, Sanjay M; Gupta, Alejandro J et al. (2018) Linking single-cell measurements of mass, growth rate, and gene expression. Genome Biol 19:207 |
| Tang, Li; Zheng, Yiran; Melo, Mariane Bandeira et al. (2018) Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat Biotechnol 36:707-716 |
| Holec, Patrick V; Berleant, Joseph; Bathe, Mark et al. (2018) A Bayesian framework for high-throughput T cell receptor pairing. Bioinformatics : |
| Wong, Madeline Y; Doan, Ngoc Duc; DiChiara, Andrew S et al. (2018) A High-Throughput Assay for Collagen Secretion Suggests an Unanticipated Role for Hsp90 in Collagen Production. Biochemistry 57:2814-2827 |
| Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604 |
Showing the most recent 10 out of 904 publications
